Electrocardiograms for cardiomyopathy risk stratification in children with anthracycline exposure

Lajja Desai¹,²*, Lauren Balmert², Jennifer Reichel²,³, Amanda Hauck¹,², Katheryn Gambetta¹,² and Gregory Webster¹,²

Abstract

Background: Early recognition of anthracycline-induced cardiomyopathy may reduce morbidity and mortality in children, but risk stratification tools are lacking. This study evaluates whether electrocardiogram (ECG) changes precede echocardiographic abnormalities in children with anthracycline-induced cardiomyopathy.

Methods: We performed a retrospective analysis of 589 pediatric cancer patients who received anthracyclines at a tertiary referral center. ECG endpoints were sum of absolute QRS amplitudes in the 6 limb leads (ΣQRS(6 L)) and corrected QT interval (QTc). Cardiomyopathy was defined by echocardiogram as ejection fraction < 50%, shortening fraction < 26%, or left ventricular end-diastolic diameter z-score > 2.5.

Results: Median age at start of therapy was 7.8 years (IQR 3.7–13.6); median follow-up time was 3.6 years (IQR 1.1–5.8). 19.5% of patients met criteria for cardiomyopathy. Male sex, race, older age at first dose, and larger body surface area were associated with development of cardiomyopathy. A 0.6 mV decrease in ΣQRS(6 L) and 10 ms increase in QTc were associated with an increased risk of developing cardiomyopathy with hazard ratios of 1.174 (95% CI = 1.057–1.304, p= 0.003) and 1.098 (95%CI = 1.027–1.173, p= 0.006) respectively. Kaplan-Meier estimates showed a lower chance of cardiomyopathy-free survival for QTc ≥ 440 ms and ΣQRS(6 L) ≤ 3.2 mV over time. After controlling for confounders, total anthracycline dose predicted a decrease in ΣQRS(6 L) and an increase in QTc independent of cardiomyopathy status (p = 0.01 and p < 0.001 respectively). Cardiotoxic radiation did not predict changes in ECG parameters. Cardiomyopathy was associated with increased mortality (34% versus 12%, p < 0.001).

Conclusion: In children receiving anthracyclines, decrease in ΣQRS(6 L) and QTc prolongation are associated with increased risk of developing cardiomyopathy. ECG is a potential non-invasive risk stratification tool for prediction of anthracycline-induced cardiomyopathy and requires prospective validation.

Keywords: Pediatric oncology, Cardiomyopathy, Electrocardiograms, Anthracyclines

Background

Anthracyclines are an important component of chemotherapy in pediatrics; however, they carry cardiotoxic risk [1]. Prevention or early recognition of anthracycline-induced cardiomyopathy is important in children to reduce long-term morbidity and mortality. Anthracycline-induced cardiomyopathy can develop acutely (within the first week of drug exposure), early (within one year of drug exposure) or late (greater than one year after drug exposure). Early toxicity may be reversed with discontinuation of the drug, which makes timely recognition of cardiomyopathy especially crucial. Previously studied risk factors for anthracycline-induced cardiomyopathy include cumulative dose of anthracyclines received, rate of exposure, concomitant exposure to cranial or mediastinal radiation, female sex, age at drug exposure, black race, and genetic predisposition [1–6].

Although there are long-term cardiotoxicity screening guidelines for survivors of childhood, adolescent and...
young adult cancers developed by The Children’s Oncology Group (COG), there continues to be debate on the diagnostic modalities to use and frequency of monitoring. Additionally, there are no current guidelines on the timing or type of cardiac testing outside of echocardiograms that should be done for children during anthracycline treatment and in the acute and early exposure period [1–3, 7]. Myocardial damage may occur before echocardiographic changes, making it important to investigate potential predictive testing. Electrocardiograms (ECGs) are a core diagnostic testing modality in cardiac care and expert interpretation is readily available. Additionally, ECGs are inexpensive and technically straightforward to obtain. Preliminary studies have evaluated ECG changes after anthracycline exposure; however, these changes have not been extensively studied in larger or primarily pediatric cohorts [1, 8–11].

This study aims to evaluate ECG findings in children at a tertiary care institution who have received anthracycline therapy and determine if ECG changes precede echocardiographic findings of cardiomyopathy. This may help answer whether ECGs can serve as a non-invasive tool to screen for cardiomyopathy during and after anthracycline therapy.

Methods

Characteristics of participants and inclusion/exclusion criteria
This was a retrospective cohort study at a tertiary care pediatric referral center using electronic medical records and the institution’s oncology pharmacy database. Institutional review board approval was obtained in this HIPAA-compliant study. Informed consent was not required. All pediatric patients from 2006 to 2014 who received anthracyclines as part of their chemotherapy regimen were included in the study population. Echocardiograms were typically obtained by the patient’s oncology team based on COG guidelines unless additional testing was deemed necessary based on the patient’s clinical status. Other cardiac testing was obtained by the patient’s care team based on clinical judgement, so patients did not undergo a pre-specified ECG protocol. Patients without an ECG or echocardiogram were excluded from analysis.

ECG evaluation

All ECGs were recorded and analyzed on a digital system (MUSE SP2 v8.0, General Electric Corporation). ECGs were digitized at 500 Hz, and measurements were verified manually by a single investigator (LD) blinded to knowledge of the echocardiographic findings. Two ECG endpoints were pre-specified: the sum of absolute QRS amplitudes in the 6 limb leads (ΣQRS(6 L)) and the corrected QT (QTc) interval. These endpoints were chosen based on preliminary data from previously published work [8, 9, 11]. Amplitudes were measured in millivolts (mV) from peak to trough of the QRS. The QTc was measured in milliseconds (ms) using Bazett’s formula and standard T-wave tangent methodology [12].

Echocardiogram evaluation

Due to lack of clear consensus on echocardiographic parameters for definition of cardiomyopathy, cardiomyopathy was defined based on clinically actionable thresholds both at our institution and in the literature [7, 13–17]. Patients met criteria for cardiomyopathy by either having systolic dysfunction or a dilated left ventricle. Systolic dysfunction was defined by either an ejection fraction (EF) less than 50% or a shortening fraction (SF) less than 26%. A dilated left ventricle was defined by a left ventricular end diastolic dimension (LVEDD) z-score greater than 2.5. EF of < 50% was chosen as this value necessitates echocardiographic reassessment, consideration of chemotherapy change, and possible heart failure treatment [16]. SF of < 26% was based on its correlation to an EF of approximately 50% with m-mode extrapolation and the pediatric oncology standards for change in anthracycline therapy at our institution. LVEDD z-score > 2.5 was included in our analysis since dilated cardiomyopathy can also occur secondary to anthracycline therapy and may require intervention and/or treatment modification [18].

Statistical analysis

Patient characteristics were summarized using descriptive statistics including mean, standard deviations, median values and interquartile ranges as appropriate. Categorical variables were summarized using counts and percentages. Comparisons between groups by cardiomyopathy status were based on either two-sample t-tests or Wilcoxon’s rank sum test (for continuous variables) and the Chi-square or Fisher’s exact test (for categorical variables). A two-sided p-value < 0.05 was considered statistically significant, and no adjustments for multiplicity were made.

Cox regression models with time-dependent covariates explored associations between ECG measures and time from first ECG to development of cardiomyopathy. Subjects were included if they had at least one ECG prior to the echocardiogram identifying cardiomyopathy, and for censored subjects at least one ECG prior to the last negative echocardiogram. A 0.6 mV change in ΣQRS(6 L) was chosen as the initial unit for evaluation because each vertical box represents 0.1 mV on a standard ECG, and an average amplitude change of less than 1 box per lead is difficult to measure in clinical practice. A 10 ms change in QTc interval was chosen as the initial unit for evaluation because it is typically the minimum clinically relevant interval.
Receiver operating characteristic curves of QTc and ΣQRS (6 L) values on the ECGs prior to the echocardiograms showing cardiomyopathy were created to determine Youden’s cutoff for each measure - the point where sensitivity and specificity of the measure is maximized. This cutoff was determined to be 440 ms for the QTc (PPV = 0.273, NPV 0.857) and 3.2 mV (PPV = 0.268, NPV 0.849) for the ΣQRS (6 L). These cutoffs were then used for Kaplan-Meier estimates to demonstrate the probability of developing cardiomyopathy in patients stratified by QTc intervals ≥ 440 ms and < 440 ms and ΣQRS (6 L) ≤ 3.2 mV and > 3.2 mV (on ECGs prior to development of cardiomyopathy or last negative echocardiogram) both from the time of ECG and from the time of therapy completion.

Differences in ΣQRS(6 L) and QTc interval between ECGs before and after anthracycline therapy were compared for the subset of patients with available data. Multiple linear regression models were used to assess the effect of anthracycline dose and cardiotoxic radiation on post-therapy ECG measures adjusting for potential confounders including sex, age at first dose, body surface area (BSA), race (white, black, Hispanic, other), time between pre- and post-therapy ECGs, and pre-therapy ECG measurements. Cardiotoxic radiation was calculated as the total radiation dose a patient received to body fields that are reported to increase the risk of cardiotoxicity by COG [12]. Lastly, changes in ECG measures by cardiomyopathy status were compared using independent two-sample t-tests. In this analysis, post-treatment ECG was defined as the closest ECG on or after development of cardiomyopathy or the closest ECG on or after the last available echocardiogram in patients without cardiomyopathy. Patients were excluded if they did not have an ECG meeting this post-treatment definition or if their first ECG was after development of cardiomyopathy.

Results

Overall cohort
There were 691 eligible pediatric patients in the study period, of which 102 patients were removed because an ECG was not available. The flow diagram in Fig. 1 provides details on the number of patients included for each analysis.

Patient characteristics and predictors of cardiomyopathy
The median age at the start of anthracycline therapy was 7.8 years (IQR 3.7–13.6). The median follow-up time after completion of anthracycline therapy to last ECG or echocardiogram was 3.6 years (IQR 1.1–5.8). There were 115 patients (19.5%) who met criteria for cardiomyopathy. Male sex, race, older age at first dose, larger BSA and total anthracycline dose were associated with development of cardiomyopathy (Table 1). Cardiomyopathy was associated with increased mortality (34% versus 12%, p < 0.001).
More patients met criteria for cardiomyopathy based on systolic dysfunction parameters versus left ventricular dilation (79% versus 19%) with 2% meeting criteria for both. The median time to development of cardiomyopathy after initiation of anthracycline therapy was 0.1 years (0 – 0.7). A majority of patients developed cardiomyopathy in the acute/early period of ≤ 1 year after start of therapy (N = 87/115, 76%). Among the 87 patients who developed cardiomyopathy in the acute/early period, 25 patients developed cardiomyopathy before the last dose of anthracycline was administered.

### Sub-group analysis: ECG measures as predictors of cardiomyopathy (n = 480/589)

The median number of ECGs prior to the echocardiogram identifying cardiomyopathy or the last negative echocardiogram was 2 with a range of 1 to 50 ECGs. This median value was consistent between both cohorts with and without cardiomyopathy. Cox models with time-dependent ECG predictors identified a hazard ratio of 1.174 (17% increased risk of developing cardiomyopathy, \( p = 0.003 \)) for a 0.6 mv decrease in \( \Sigma QRS(6 \text{ L}) \) and a hazard ratio of 1.098 (10% increased risk of developing cardiomyopathy, \( p = 0.006 \)) for a 10 ms increase in QTc interval (Table 2). The forest plots in Fig. 2 show the hazard ratios with 95% confidence intervals for additional \( \Sigma QRS(6 \text{ L}) \) and QTc values. The hazard ratio increases as the \( \Sigma QRS(6 \text{ L}) \) decreases and as the QTc interval increases.

The median time from the most recent ECG prior to the first indication of cardiomyopathy was 86 days (IQR 8 – 209), and the median time from the first available ECG to next echocardiogram was 91 days (IQR 19 – 336). The median time from the start of treatment to the first

### Table 1 Patient demographics and treatment characteristics by cardiomyopathy status

|                         | Cardiomyopathy (N = 115, 19.5%) | No Cardiomyopathy (N = 474, 80.5%) | \( p \)-value |
|-------------------------|---------------------------------|------------------------------------|--------------|
| **Sex**                 |                                 |                                    |              |
| Male                    | 73 (63.5)                       | 249 (52.5)                         | 0.03         |
| Female                  | 42 (36.5)                       | 225 (47.5)                         |              |
| **Age at First Dose (years)** | 10.8 (4.9–15.1)                  | 7.1 (3.4–12.9)                     | < 0.001      |
| **Race**                |                                 |                                    |              |
| White                   | 57 (50.4)                       | 244 (51.6)                         | 0.03         |
| Hispanic                | 32 (28.3)                       | 160 (33.8)                         |              |
| Black                   | 18 (15.9)                       | 34 (7.2)                           |              |
| Other (including Asian) | 6 (5.3)                         | 35 (7.4)                           |              |
| Unknown                 | 2 (1.7)                         | 1 (0.2)                            |              |
| **Body Surface Area (m²)** | 1.20 (0.74–1.66)                | 0.88 (0.62–1.42)                   | < 0.001      |
| **Diagnosis**           |                                 |                                    |              |
| Leukemia                | 57 (49.6)                       | 253 (53.4)                         | 0.08         |
| Solid Tumors            | 36 (31.3)                       | 126 (26.6)                         |              |
| Lymphoma                | 17 (14.8)                       | 82 (17.3)                          |              |
| Brain Tumors            | 1 (0.9)                         | 10 (2.1)                           |              |
| Multiple Diagnoses      | 4 (3.5)                         | 3 (0.6)                            |              |
| **Anthracycline Dose Total (mg/m²)** | 236.0 (153.0–329.0)          | 164.5 (92.0–232.0)                 | < 0.001      |
| **Cardiotoxic Radiation** |                                 |                                    |              |
| Yes                     | 42 (36.5)                       | 152 (32.1)                         | 0.36         |
| No                      | 73 (63.5)                       | 322 (55.7)                         |              |
| **Vital Status**        |                                 |                                    |              |
| Alive                   | 76 (66.1)                       | 417 (88.0)                         | < 0.001      |
| Died                    | 39 (33.9)                       | 57 (12.0)                          |              |

*Data presented as number of patients(%) or median (interquartile range)*

### Table 2 Cox regression models with ECG measures as predictors for time to development of cardiomyopathy (N = 480)

| Model | Covariate | Unit Change | Hazard Ratio | 95% CI | \( p \)-value |
|-------|-----------|-------------|--------------|--------|--------------|
| 1     | \( \Sigma QRS(6 \text{ L}) \) | 0.6 mV | 1.174 | 1.057–1.304 | 0.003 |
| 2     | QTc       | 10 ms      | 1.098 | 1.027–1.173 | 0.006 |

*ECG measures were evaluated as time-dependent covariates \( \Sigma QRS(6 \text{ L}) \): sum of QRS amplitude in 6 electrocardiogram limb leads, QTc: corrected QT interval*
available ECG was 1 day (IQR 34 to 38). The median time from the start of treatment to the next available ECG was 110 days (IQR 31–364). Figure 3 shows the time to development of cardiomyopathy stratified by ECG cutoffs as determined by Youden’s index. The probability that a patient develops cardiomyopathy over time is higher for patients who have an ECG with QTc ≥ 440 ms or ΣQRS (6 L) ≤ 3.2 mV both from the time of ECG and from the time of therapy completion.

Sub-group analysis: effect of therapy on ECG parameters based on cardiomyopathy status (n = 143/589)

There were 62 patients (25%) in this sub-group who met criteria for cardiomyopathy with 11 patients developing cardiomyopathy before completing therapy. When comparing the change in ECG parameters before and after anthracycline therapy in the cardiomyopathy versus no cardiomyopathy group, there was a greater decrease in ΣQRS(6 L) in the cardiomyopathy group (Table 5). Although there was no statistically significant difference in the QTc interval change between these groups, the data trended in the expected direction with a greater increase on average in patients who developed cardiomyopathy (Table 5).

Discussion

Our study demonstrates that clinically measurable ECG changes, specifically a decrease in ΣQRS(6 L) and prolongation of the QTc interval, are associated with an increased risk of developing anthracycline-induced cardiomyopathy. As survival rates have improved in pediatric oncology, focus has shifted on reducing associated morbidities like cardiotoxicity to ensure long-term quality of life [19]. Reduction, recognition and treatment of these morbidities via personalized cancer therapy requires consideration of baseline patient factors, identification of risk stratification tools during and after therapy, and clear definitions of the adverse outcome. Figure 4 shows a representation of this process for pediatric anthracycline-induced cardiomyopathy. Supported by our study and prior literature, multiple baseline biologic (sex, gender, age, race, BSA, genetics) and environmental (anthracycline dose, radiation) factors can contribute to a patient’s risk of developing cardiomyopathy [1–6]. Cardiomyopathy is typically recognized via echocardiographic and/or clinical manifestations. Our study focuses on the period of surveillance after treatment is initiated to identify a potential screening tool for the cardiomyopathy endpoint. Based on our findings, ECGs are an inexpensive and readily available tool that may aid in evaluation of individual patient risk during and after therapy. ECGs should be considered as part of comprehensive cardio-oncology surveillance, but a specific protocol for screening cannot be established without prospective study design.

Existing literature has attempted to show a relationship between ECG measures after anthracycline therapy and echocardiographic findings. An initial study analyzed ECGs for pediatric patients treated
with Adriamycin at specified intervals after completion of chemotherapy: 2 months, 1 year, and 3 years [20]. Although a higher rate of cardiomyopathy-free survival for QTc \( \geq 440 \) ms ("high") and \( \Sigma QRS(6L) \leq 3.2 \) mV ("low") over time. Time "zero" for column a \((n=480)\) is the electrocardiogram (ECG) preceding echocardiographic evidence of cardiomyopathy and for column b \((n=303)\) is the last anthracycline treatment dose. The patients in column b are the subset from column a who had completed chemotherapy at the time of ECG analysis.

A more recent analysis by Markman et al. attempted a similar approach to our study to determine if an ECG finding, specifically the QTc interval, precedes development of left ventricular dysfunction defined by shortening fraction [8]. A Kaplan-Meier estimate showed a higher cumulative rate of left ventricular dysfunction in patients who had a maximum QTc \( > 450 \) ms at any point

### Table 3

Comparison of ECG measures before and after therapy \((N = 248)\)

|                      | Before therapy | After therapy | \( P \)-value |
|----------------------|----------------|---------------|--------------|
| \( \Sigma QRS(6L) \) (mV) | 4.2 (3.2–5.0) | 3.9 (3.2–4.9) | 0.01         |
| QTc (mS)             | 427.0 ± 20.9   | 431.2 ± 25.5  | 0.02         |

\( ^a \)Data presented as median (interquartile range) or mean ± standard deviation

\( \Sigma QRS(6L) \): sum of QRS amplitudes in 6 electrocardiogram limb leads,

QTc: corrected QT interval

### Table 4

Multiple linear regression models\(^a\) showing effect of anthracycline dose on post-therapy ecg measures \((N = 248)\)

| Model | Outcome | Anthracycline dose \( \text{estimate (mg/m2)} \) | 95% CI | \( P \)-value |
|-------|---------|-----------------------------------------------|-------|--------------|
| 1     | \( \Sigma QRS(6L) \) | - 0.001 | - 0.002 to –0.003 | 0.01  |
| 2     | QTc     | + 0.06 | + 0.03 to + 0.09  | < 0.001|

\(^a\)Adjusted for sex, age at first dose, body surface area, race (white, black, Hispanic, other), time between pre- and post-therapy ECG measures, and pre-therapy ECG measures

\( \Sigma QRS(6L) \): sum of QRS amplitudes in 6 electrocardiogram limb leads,

QTc: corrected QT interval
during the study period, including after the development of cardiomyopathy. The definition of left ventricular dysfunction was unclear in this second analysis. Although this study had more patients than prior studies, authors suggested they had limited numbers for sufficient power, and their study population only involved patients > 18 years of age.

Our study expands on the concept presented by prior literature by analyzing a larger patient cohort, including a more consistent and comprehensive definition of cardiomyopathy, evaluating an additional ECG parameter of $\Sigma$QRS (6L), determining cutoffs for QTc and $\Sigma$QRS (6L) using a receiver operating characteristic curve, and using only ECG values that precede development of cardiomyopathy for analysis. Additionally, we show how changes to ECG measures over time affect the risk of developing cardiomyopathy.

Anthracycline therapy has been shown to prolong the QTc interval in prior small studies in adult survivors of either pediatric or adult malignancies [8, 9, 11]. A slightly larger pediatric study with 100 patients also showed QTc prolongation after anthracycline therapy [10]. Decreases in QRS voltages have been associated with left ventricular dysfunction on echocardiogram both after anthracycline use and in patients with heart failure due to other causes [9, 21]. While the total anthracycline dose was shown to decrease the $\Sigma$QRS(6L) and prolong the QTc interval in our study, the data suggest the magnitude of ECG changes due to development of cardiomyopathy were larger than changes due to anthracycline exposure alone. In addition, cardiotoxic radiation therapy did not alter the $\Sigma$QRS(6L) or QTc interval, suggesting the ECG changes in patients exposed to anthracyclines should not be dismissed as secondary to therapeutic radiation exposure. A prospective long-term study should be considered to reproduce our results using a systematic approach, and we established $\Sigma$QRS(6L) and QTc as two appropriate outcome measures for evaluation.

A large percentage of patients in this study met echocardiographic criteria for cardiomyopathy in the acute/early period (76%, $n = 87$) with some patients even developing toxicity before the last dose of an anthracycline was given ($n = 25/87$). The patients who developed cardiomyopathy before their last dose of anthracyclines may have the most potential to benefit from ECG-based risk stratification, since heart failure therapy could be initiated and treatment protocols modified before echocardiographic changes are noted [22]. As development of cardiomyopathy was associated with mortality, this further supports early incorporation of ECG surveillance.

There are limitations to this study, particularly due to its retrospective nature. Each patient’s clinical team determined when to obtain ECGs since a specific guideline is not currently available. This could potentially create bias in the study as patients with clinical concern may have more data points for analysis and could have extrinsic causes for ECG findings related to their complex oncologic care (i.e. electrolyte disturbance). This was somewhat mitigated by our inclusion of both patients with and without cardiomyopathy in the Cox and Kaplan-Meier analyses with a consistent median number of ECGs for patients with and without development of cardiomyopathy. Additionally, dichotomization of the primary predictor variable (presence or absence of cardiomyopathy) can be a subjective process, especially when performed using only echocardiographic means without clinical correlation. There is suggestion in small

### Table 5: Pre- and post-treatment ECG changes in patients by cardiomyopathy status (N = 143)

| Cardiomyopathy | No Cardiomyopathy | P-value |
|----------------|-------------------|---------|
| ($N = 53$)     | ($N = 90$)        |         |
| Change in $\Sigma$QRS (6L) | $-0.6 \pm 1.0$ | $-0.2 \pm 1.1$ | 0.02 |
| Change in QTc  | $7.5 \pm 35.5$   | $4.6 \pm 31.5$ | 0.61 |

*Data presented as mean ± standard deviation
$\Sigma$QRS(6L): sum of QRS amplitudes in 6 electrocardiogram limb leads, QTc: corrected QT interval

---

**Fig. 4** Multiple factors increase a patient’s risk of anthracycline-induced cardiomyopathy in children. ECGs may identify these patients before echocardiographic and clinical changes. *Genetics was not evaluated in this study. †Cardiotoxic radiation has been previously described as a risk factor but did not have a statistical association with cardiomyopathy in this study.**
pediatric studies that diastolic dysfunction can occur as part of anthracycline related cardiotoxicity even at lower anthracycline doses [23, 24]. Diastolic dysfunction was not studied as an outcome variable in this study due to inconsistent availability of diastolic interpretation. Modern imaging modalities and techniques such as 3D echocardiography, strain and magnetic resonance imaging may be useful to detect early cardiotoxicity in these patients; however this data was also not consistently available for our review during the available study period. Finally, our study had variable follow-up periods for each patient and could not assess all late-onset cardiomyopathy patients. This may affect interpretation of the predictors risk factors of cardiotoxicity. For example, female sex has been shown in prior literature to be a predictor for late development of cardiomyopathy [4]. In our study, male sex was associated with the development of cardiomyopathy, possibly due to the shorter available follow-up period and the cohort being restricted to pediatrics. Additionally, prior literature has shown younger age at diagnosis to be a predictor for development of cardiomyopathy [1]. Although our study contradicts the prior literature and finds that older age at diagnosis increases the risk of cardiomyopathy, this may again be due to the tighter age range of our study population and limited available follow-up time.

**Conclusion**

A decrease in ΣQRS(6 L) or prolongation of the QTc interval increases the risk of developing cardiomyopathy in pediatric patients receiving anthracycline therapy. Higher total anthracycline doses were associated with decreases in the ΣQRS(6 L) and prolongation of the QTc interval. The decrease in ΣQRS(6 L) after therapy was greater in patients who developed cardiomyopathy. Cardiotoxic radiation was not associated with changes in the ECG parameters measured. ECGs are a potential non-invasive, inexpensive tool for prediction of anthracycline-induced cardiomyopathy and require prospective validation. Incorporation of ECG evaluation in cardio-oncology monitoring regimens in pediatric patients should be carefully considered.

**Abbreviations**

BSA: body surface area; COG: Children’s Oncology Group; ECG: Electrocardiogram; EF: Ejection fraction; LVEDD: Left ventricular end diastolic dimension; ms: millisecond; mV: millivolt; QTc: corrected QTc interval; SF: Shortening fraction; ΣQRS(6 L): sum of absolute QRS amplitudes in the 6 limb leads

**Acknowledgements**

Not applicable.

**Authors’ contributions**

LD conceptualized and designed the study, created the data collection instruments, collected the data, interpreted the data analysis, drafted the initial manuscript, and reviewed and revised the manuscript. LB analyzed and interpreted the data, and reviewed and revised the manuscript critically for important intellectual content. JR designed the study analysis, interpreted the data, and critically reviewed and revised the manuscript for important intellectual content. AH and KG conceptualized and designed the study, and critically reviewed and revised the manuscript for important intellectual content. GW conceptualized and designed the study, designed the data collection instruments, interpreted the data analysis, and reviewed the revised manuscript critically for important intellectual content. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

**Funding**

Research reported in this publication was supported in part by the National Institutes of Health’s National Center for Advancing Translational Sciences Grant Number TL1TR001423 and by the National Institutes of Health’s National Heart, Lung and Blood Institute Grant Number K23HL130554. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

Institutional review board approval was obtained in this HIPAA-compliant study. Informed consent was not required.

**Consent for publications**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1Division of Cardiology, Ann and Robert H. Lurie Children’s Hospital of Chicago, 225 East Chicago Avenue, Box 21, Chicago, IL 60611, USA. 2Northwestern University Feinberg School of Medicine, 420 East Superior Street, Chicago, IL 60611, USA. 3Division of Hematology/Oncology, Ann and Robert H. Lurie Children’s Hospital of Chicago, 225 East Chicago Avenue, Box 30, Chicago, IL 60611, USA.

Received: 13 March 2019 Accepted: 28 June 2019 Published online: 07 August 2019

**References**

1. Lipshultz SE, Adams MJ, Colan SD, Constine LS, Herman EH, Hsu DT, Hudson MM, Kremer LC, Landy DC, Miller TL, Oeffinger KC, Rosenthal DN, Sable CA, Sallan SE, Singh GK, Steinberger J, Cochran TR, Wilkinson JD. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy. Circulation. 2013;128:1927–95. https://doi.org/10.1161/CIRCULATIONAHA.113.003889.
2. Simbre VC, Duffy SA, Dadhani GH, Miller TL, Lipshultz SE. Cardiotoxicity of cancer chemotherapy. Pediatr Drugs. 2005;7:187–202.
3. Shankar SM, Marina N, Hudson MM, Hodgson DC, Adams MJ, Landier W, Bhatia S, Meeseke K, Hui Chen M, Kinahan KE, Steinberger J, Rosenthal D. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the cardiovascular disease task force of the children’s oncology group. Pediatrics. 2008;121:e187–96. https://doi.org/10.1542/peds.2007-0575.
4. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, Otav EJ, Gelber RD, Colan SD. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738–43. https://doi.org/10.1056/NEJM199506293322602.
5. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808–15. https://doi.org/10.1056/NEJM199103213241205.
6. Sorensen K, Levitt G, Bull C, Dorup I, Sullivan ID. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer. 2003;97:1991–8. https://doi.org/10.1002/cncr.11274.
7. Van Dalen EC, Van der Burg M, Caron HN, Kremer LC. Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. Eur J Cancer. 2006;42:1959–205. https://doi.org/10.1016/j.ejca.2006.08.002.

8. Markman TM, Ruble K, Loeb D, Chen A, Zhang Y, Beasley GS, Thompson WR, Nazarian S. Electrophysiological effects of anthracyclines in adult survivors of pediatric malignancy. Pediatr Blood Cancer. 2017;64:e26556. https://doi.org/10.1002/pbc.26556.

9. Horacek JM, Jakl M, Horackova J, Pudli R, Jebavy L, Maly J. Assessment of anthracycline-induced cardiotoxicity with electrocardiography. Exp Oncol. 2009;31:115–7.

10. Larsen RL, Jakacki RI, Vetter VL, Meadows AT, Silber JH, Barber G. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol. 1992;70:73–7.

11. Schwartz CL, Hobbie WL, Truesdell S, Constance LC, Clark EB. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol. 1993;11:1906–10. https://doi.org/10.1200/JCO.1993.11.10.1906.

12. Postema PG, De Jong JS, Van der Bilt IA, Wilde AA. Accurate electrocardiographic assessment of the QT interval teach the tangent. Heart Rhythm. 2008;5:1015–8. https://doi.org/10.1016/J.hrthm.2008.03.037.

13. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Cristielli C, Goldhirsh A, Cipolla C, Rolla F. Cardiovascular toxicity induced by chemotherapy, targeted agents, and radiotherapy. ESMO clinical practice guidelines. Ann Oncol. 2012;23(Suppl 7):vii155–66. https://doi.org/10.1093/annonc/mds293.

14. Piper SE, McDonagh TA. Chemotherapy-related cardiomyopathy. European Cardiology Review. 2015;10(1):19–24. https://doi.org/10.15420/ecr.2015.10.01.19.

15. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003 Jun 1;97(11):2869–79. https://doi.org/10.1002/cncr.11407.

16. Chang HM, Moudgil R, Sciacabelli T, Okwuosa TM, Yeh ETH. Cardiovascular complications of Cancer therapy: best practices in diagnosis, prevention, and management: part 1. J Am Coll Cardiol. 2017 Nov 14;70(20):2536–51. https://doi.org/10.1016/j.jacc.2017.09.1096.

17. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lennihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Tornicki A, Suter TM. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–801. https://doi.org/10.1093/eurheartj/ehw211.

18. Armenian SH, Gelehrter SK, Vase T, Venkataraman R, Landier W, Wilson KD, Herera C, Reichman J, Muntean H, Freyer DR, Venkataraman K, Bhata S. Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors. Clin Cancer Res. 2014;20(34):1–23. https://doi.org/10.1158/1078-0432.CCR-13-3440.

19. Children’s Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. Version 4.0. Monrovia, CA: Children’s Oncology Group; 2013.

20. Ferrari S, Figus E, Cagnano R, Iantorno D, Bacci G. The role of corrected QT interval in the cardiologic follow-up of young patients treated with Adriamycin. J Chemother. 1996;8:232–6. https://doi.org/10.1179/joc.1996.8.3.232.

21. Kataoka H, Madias JE. Changes in the amplitude of electrocardiogram QRS complexes during follow-up of heart failure patients. J Electrocardiol. 2001;34:91–9. https://doi.org/10.1016/S0022-0703(01)00148-4.

22. Cardinale D, Colombo A, Bacchieri G, Tedeschi I, Miseroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981–8. https://doi.org/10.1161/CIRCULATIONAHA.114.013777.

23. Alehan D, Sahin M, Varan A, Arden M, Küpeli S, Büyükpamukçu M. Late evaluation of systolic and diastolic cardiac functions in long-term survivors of Hodgkin lymphoma. Pediatr Blood Cancer. 2012;58:250–5. https://doi.org/10.1002/pbc.23281.

24. Iarussi D, Galderisi M, Ratti G, Tedesco MA, Indolfi P, Canale F, Di Tullio MT, de Dixit R, Iacono A. Left ventricular systolic and diastolic function after anthracycline chemotherapy in childhood. Clin Cardiol. 2001;24:663–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.